commercial mortgage rate src="http://i.imgur.com/CpMbHMn.jpg" width="400" align="right" title="" alt=""/> The Series B financing was co-led by Abingworth and Canaan Partners with investments from Lightstone Ventures and existing Series A investors, including MPM Capital, Amgen Ventures, Astellas Venture Management and InterWest Partners. As part of the financing, Shelley Chu, M.D., Ph.D., Partner of Abingworth, Nina Kjellson, Partner of Canaan Partners, and Jean George, General Partner of Lightstone Ventures, have joined Tizonas Board of Directors. We expect Tizonas anti-CCR4 antibody to play an important role in inducing antitumor activity by depleting regulatory T cells (Tregs), a type of cell crucial to establishing and maintaining an immunosuppressive tumor microenvironment, said Pablo J. Cagnoni, M.D., President and Chief Executive Officer of Tizona. We have an opportunity to contribute a potentially valuable new addition to the group of novel immunotherapies that is changing stan

This URL was also folkd by: